This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday to their inbox.
There is now a drug on the U.S. market, approved this week, called Bkemv. I’m not kidding. I wish I were.
I’m flying to Chicago today for the ASCO meeting. I’ll be posting cancer-related dispatches all weekend, in case you need something to read on the beach.
Novo Nordisk has asked the Food and Drug Administration to bar compounding pharmacies from making copies of its blockbuster weight loss drug semaglutide, arguing that
Cell Signaling Technology (CST), a life science discovery technology company and leading provider of antibodies, kits, and services, today announced a partnership with global green
Horizon Therapeutics disclosed Friday afternoon that its antibody drug daxdilimab failed a mid-stage study for lupus. In the 214-patient Phase II trial, there was no
